GSK1349572 (dolutegravir) + raltegravir
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infection, Human Immunodeficiency Virus I
Conditions
Infection, Human Immunodeficiency Virus I
Trial Timeline
Oct 19, 2010 → Dec 27, 2016
NCT ID
NCT01227824About GSK1349572 (dolutegravir) + raltegravir
GSK1349572 (dolutegravir) + raltegravir is a phase 3 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus I. The current trial status is completed. This product is registered under clinical trial identifier NCT01227824. Target conditions include Infection, Human Immunodeficiency Virus I.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01227824 | Phase 3 | Completed |
Competing Products
20 competing products in Infection, Human Immunodeficiency Virus I